By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Avicena Group, Inc. 

San Francisco  California    U.S.A.
Phone: N/A Fax:



Drug Discovery

Company News
Avicena Group, Inc.'s HD-02 to Proceed to National Institutes of Health (NIH) Sponsored Phase III Huntington's Disease Trial 3/12/2008 9:19:33 AM
Avicena Group, Inc. Announces Positive Phase II Data for a Combination Trial Involving AL-08 for the Treatment of Amyotrophic Lateral Sclerosis 12/3/2007 8:15:41 AM
Data on Avicena Group, Inc.'s Drug Candidate HD-02 Presented at the 2007 World Congress on Huntington's Disease 11/19/2007 7:54:26 AM
USPTO Issues Patent for Avicena Group, Inc.'s Proprietary Compounds to Treat Amyotrophic Lateral Sclerosis Patent Expands Existing IP to Treat ALS 11/13/2007 7:49:49 AM
Survival Data for Avicena Group, Inc.'s Amyotrophic Lateral Sclerosis Drug Candidate, AL-02, to be Presented at 18th International Symposium on ALS/MND 10/18/2007 10:48:23 AM
Avicena Group, Inc. Appoints Dr. Belinda Tsao-Nivaggioli as Chairman of the Board of Directors 10/11/2007 10:08:54 AM
Avicena Group, Inc. to Present at 4th Annual Biotechnology Industry Organization (BIO) InvestorForum Conference Expansion of Drug Pipeline and Advancement of Clinical Programs 10/9/2007 11:39:31 AM
Avicena Group, Inc. Appoints Dr. M. Flint Beal to Board of Directors 9/28/2007 12:53:46 PM
Avicena Group, Inc. Announces Closing of Private Offering 9/26/2007 11:44:17 AM
Avicena Group, Inc. Reports Second Quarter 2007 Results 9/4/2007 8:09:10 AM